All In Biotech

Drug Trial Radar · NCT01499368

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 495 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

495

Actual

Start

Nov 2011

Primary completion

Nov 2012

Study completion Nov 2012

Sponsor

Sponsor type
Industry
First posted
Dec 26, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the healing rate and safety of Lafutidine in erosive esophagitis

Conditions

  • Erosive Esophagitis

Interventions

  • LafutidineDrug

    Lafutidine 20mg/day

  • FamotidineDrug

    Famotidine 40mg/day

  • OmeprazoleDrug

    Omeprazole 20mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recovery Rates of Reflux EsophagitisTime frame: 8 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.